Prodrug Nanosensitizer Overcomes the Radiation Resistance of Hypoxic Tumor

• DOI: 10.1021/acsami.2c14628
• Publication Date: 2022-12-16T20:03:15Z
• Authors: Lili Qian; Qian Li; Zhenshan Ding; Kejun Luo; Jiamin Su; Jiawei Chen; Guangying Zhu; Zhihua Gan; Qingsong Yu
• Keywords: 0301 basic medicine; Radiation-Sensitizing Agents; 03 medical and health sciences; DNA Repair; Neoplasms; Cell Line, Tumor; Humans; Prodrugs; Hypoxia

Clinical radiation therapy (RT) is often hindered by the low radiation energy absorption coefficient and the hypoxic features of tumor tissues. Among the tremendous efforts devoted to overcoming the barriers to efficient RT, the application of hypoxic radiosensitizers and cell-cycle-specific chemotherapeutics has shown great potential. However, their effectiveness is often compromised by their limited bioavailability, especially in the hypoxic region, which plays a major role in radioresistance. Herein, to simultaneously improve the delivery efficacy of both hypoxic radiosensitizer and cell-cycle-specific drug, a gambogic acid (GA) metronidazole (MN) prodrug (GM) was designed and synthesized based on GA, a naturally occurring chemotherapeutic and multiple pathway inhibitor, and MN, a typical hypoxic radiosensitizer. In combination with MN-containing block copolymers, the prodrug nanosensitizer (NS) of GM was obtained. Owing to the bioreduction of MN, the as-designed prodrug could be efficiently delivered to hypoxic cells and act on mitochondria to cause the accumulation of reactive oxygen species. The strong G2/M phase arrest caused by the prodrug NS could further sensitize treated cells to external radiation under hypoxic conditions by increasing DNA damage and delaying DNA repair. After coadministration of the NS with a well-established tissue-penetrating peptide, efficient tumor accumulation, deep tumor penetration, and highly potent chemoradiotherapy could be achieved.